Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating Activities
Net income (loss)	$ 5,123	$ (11,950)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:
Depreciation and amortization	13,320	12,741
Amortization of deferred financing costs	625	1,023
Credit loss expense, net	220	7,229
Write-downs	304	381
Deferred income tax benefit	(193)	(109)
Share-based and other non-cash compensation	5,135	6,189
Unrealized foreign currency exchange (gain) loss	(78)	58
Realized and unrealized investment gains	(44)	(34)
Changes in assets and liabilities:
Accounts receivable	12,374	(2,654)
Inventories	(5,946)	(534)
Film assets	(3,884)	(5,107)
Deferred revenue	2,606	(830)
Changes in other operating assets and liabilities	(8,344)	(10,186)
Net cash provided by (used in) operating activities	21,218	(3,783)
Investing Activities
Purchase of property, plant and equipment	(364)	(728)
Investment in equipment for joint revenue sharing arrangements	(2,157)	(4,587)
Interest in film classified as a financial instrument		(4,731)
Acquisition of other intangible assets	(1,760)	(551)
Net cash used in investing activities	(4,281)	(10,597)
Financing Activities
Revolving credit facility borrowings	25,717
Repayments of revolving credit facility borrowings	(31,180)
Credit facility amendment fees paid		(1,783)
Other borrowings	315
Repurchase of common shares	(3,656)	(6,272)
Taxes withheld and paid on employee stock awards vested	(6,233)	(3,136)
Net cash used in financing activities	(15,037)	(13,035)
Effects of exchange rate changes on cash	(55)	4
Increase (decrease) in cash and cash equivalents during period	1,845	(27,411)
Cash and cash equivalents, beginning of period	97,401	189,711
Cash and cash equivalents, end of period	$ 99,246	162,300
IMAX China
Financing Activities
Repurchase of common shares		$ (1,844)